Point72 Europe (London) LLP Apellis Pharmaceuticals, Inc. Transaction History
Point72 Europe (London) LLP
- $1.62 Billion
- Q4 2024
A detailed history of Point72 Europe (London) LLP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Europe (London) LLP holds 192,694 shares of APLS stock, worth $5.47 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
192,694Holding current value
$5.47 Million% of portfolio
0.38%Shares
1 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
123MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$347 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$338 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$335 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$285 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$273 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.12B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...